High Net Worth Advisory Group’s Denali Therapeutics DNLI Stock Holding History

High Net Worth Advisory Group’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,000	Closed	-$27.8K	–	280
2022 Q4	$27.8K	Hold	1,000	–	–	0.01%	393
2022 Q3	$31K	Sell	1,000 -1,000	-50%	-$32.5K	0.01%	403
2022 Q2	$59K	Hold	2,000	–	–	0.02%	299
2022 Q1	$64K	Sell	2,000 -500	-20%	-$17.2K	0.02%	310
2021 Q4	$112K	Buy	+2,500	New	+$118K	0.04%	239

Other funds holding DNLI

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

High Net Worth Advisory Group's DNLI Position: Q1 2023 in Review

High Net Worth Advisory Group sold out of Denali Therapeutics (DNLI) in Q1 2023, closing a stake of 1,000 shares — an estimated $27.8K sold.

High Net Worth Advisory Group first reported a position in DNLI in Q4 2021 and held it in 5 quarters. The position peaked at $112K in Q4 2021. 202 funds tracked by Wall St. Rank hold DNLI as of Q1 2023.

High Net Worth Advisory Group reported no remaining Denali Therapeutics position as of Q1 2023 after selling out during the quarter.
High Net Worth Advisory Group sold 1,000 Denali Therapeutics shares in Q1 2023, an estimated $27.8K.
High Net Worth Advisory Group first reported a position in Denali Therapeutics in Q4 2021 and held it in 5 quarters.
High Net Worth Advisory Group's Denali Therapeutics position peaked at $112K in Q4 2021.
202 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2023.

Based on High Net Worth Advisory Group's 13F filing for Q1 2023, filed 20 Apr 2023.